Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight

Summary

DelveInsight predicts the checkpoint inhibitor refractory cancer market will grow significantly through 2036, driven by increased adoption of immune checkpoint inhibitors and growing awareness of resistance mechanisms. Multiple biopharma companies are advancing novel immuno-oncology candidates to address this market need.